https://www.bharatbook.com –
Liquid biopsy is process of obtaining non-solid tissue usually the blood and other body fluids (urine, saliva etc.) obtained non-invasively as a diagnosis and monitoring tool for disease such as cancer through identification of biomarker in form of cell-fee DNA or circulating tumor cells (CTC) to advance personalized medicine, and improve the quality of life. The groundbreaking discovery of cfDNA in 1948 has opened up to new possibilities in the field of oncology, transplantation and non-invasive prenatal screening.
The Liquid Biopsy Global Market is projected to grow at double digit CAGR to reach $8,730.4 million by 2024.
The liquid biopsy market by Biomarkers is segmented into circulating tumor cells (CTC), cell-free DNA and Exosomes & Others, among which, the Cell-free DNA market commanded the largest share of the market & growing at double digit CAGR from 2017-2024. The utilization of circulating tumor cell as an invaluable research tool is expected to propel this market at a strong CAGR from 2017 to 2024.
The applications market is segmented into oncology testing, prenatal (NIPT) testing and transplantation diagnostics where oncology testing dominates the application with market which is followed by prenatal testing (NIPT) in 2017, however, the rapid adoption of cfDNA based transplantation diagnostics testing is expected to drive this market at strong CAGR during forecasting period.
Read more »